Context. S eizures during intoxications with pharmaceuticals are a well-known complication. However, only a few studies report on drugs commonly involved and calculate the seizure potential of these drugs. Objectives. To identify the pharmaceutical drugs most commonly associated with seizures after single-agent overdose, the seizure potential of these pharmaceuticals, the age-distribution of the cases with seizures and the ingested doses. Methods. A retrospective review of acute single-agent exposures to pharmaceuticals reported to the Swiss Toxicological Information Centre (STIC) between January 1997 and December 2010 was conducted. Exposures which resulted in at least one seizure were identifi ed. The seizure potential of a pharmaceutical was calculated by dividing the number of cases with seizures by the number of all cases recorded with that pharmaceutical. Data were analyzed using descriptive statistics. Results. We identifi ed 15,441 single-agent exposures. Seizures occurred in 313 cases. The most prevalent pharmaceuticals were mefenamic acid (51 of the 313 cases), citalopram (34), trimipramine (27), venlafaxine (23), tramadol (15), diphenhydramine (14), amitriptyline (12), carbamazepine (11), maprotiline (10), and quetiapine (10). Antidepressants were involved in 136 cases. Drugs with a high seizure potential were bupropion (31.6%, seizures in 6 of 19 cases, 95% CI: 15.4 -50.0%), maprotiline (17.5%, 10/57, 95% CI: 9.8 -29.4%), venlafaxine (13.7%, 23/168, 95% CI: 9.3 -19.7%), citalopram (13.1%, 34/259, 95% CI: 9.5 -17.8%), and mefenamic acid (10.9%, 51/470, 95% CI: 8.4 -14.0%). In adolescents (15 -19y/o) 23.9% (95% CI: 17.6 -31.7%) of the cases involving mefenamic acid resulted in seizures, but only 5.7% (95% CI: 3.3 -9.7%) in adults ( Ն 20y/o; p Ͻ 0.001). For citalopram these numbers were 22.0% (95% CI: 12.8 -35.2%) and 10.9% (95% CI: 7.1 -16.4%), respectively ( p ϭ 0.058). The probability of seizures with mefenamic acid, citalopram, trimipramine, and venlafaxine increased as the ingested dose increased. Conclusions. Antidepressants were frequently associated with seizures in overdose, but other pharmaceuticals, as mefenamic acid, were also associated with seizures in a considerable number of cases. Bupropion was the pharmaceutical with the highest seizure potential even if overdose with bupropion was uncommon in our sample. Adolescents might be more susceptible to seizures after mefenamic acid overdose than adults.
Introduction
Drug-related seizures account for 1.7 -14% of all cases with acute symptomatic seizures. 1 -3 In a study from the California Poison Control System the rate of complications associated with drug-induced seizures was 60%. 4 Complications, as defi ned by the authors, were a prolonged hospital stay, endotracheal intubation, status epilepticus, anoxic brain injury or death. Despite these facts epidemiologic data are rare and only a few studies address the problem of overdose-induced seizures. 5 In four studies the incidence rates of seizures after poisoning are reported to be between 1.3% and 5.2%. 6 -9 Five studies analyzed the substances involved in poisoninginduced seizures. 4,6,9 -11 In all of them antidepressants were among the most frequent drugs and rates between 28.8% and 42.4% are reported. In four of the studies bupropion was the most prevalent pharmaceutical reported to cause seizures with rates between 14.9% and 23% of all cases. 4, 6, 9, 10 The studies published so far include cases with single-agent exposures and mixed-ingestions. Coingestants are reported in 18.4 -42% of the cases. 4, 6, 10, 11 The aim of this study was to further the understanding of drug-induced seizures. We examined which pharmaceutical exposures are commonly associated with overdose-induced seizures and the potential of these pharmaceuticals to cause seizures. Furthermore we calculated the percentage of cases with seizures for different age groups and compared the rates of adolescents (15 -19 years of age) and adults ( Ն 20 years of age). To the best of our knowledge, there are no studies that describe these aspects in single-agent overdoses with pharmaceuticals.
Methods

Data collection
The Swiss Toxicological Information Centre (STIC) provides medical advice concerning poisonings to the general public and to health professionals on a 24/7 basis.
All calls to the STIC are recorded in an in-house database system. Collected data include age, weight and sex of the patient, circumstances of poisoning, ingested dose, clinical effects, temporal course of the poisoning, results of drug screening and laboratory analysis, clinical parameters, decontamination and treatment measures, antidotes given and medical complications.
Study design
The study was conducted as a retrospective single-centre review of consecutive single-agent overdoses with pharmaceutical drugs reported to the STIC between January 1, 1997 and December 31, 2010.
Inclusion criteria
We included all acute human single-agent overdoses with a pharmaceutical drug intended for human use. Furthermore a written feedback by a physician, providing suffi cient data about clinical effects and evolution, had to be available. Among all single-agent overdoses we identifi ed cases with occurrence of seizures by searching the data fi les for key words as epileptic, seizures, or convulsions.
Only cases with a confi rmed or likely causal relationship between exposure and clinical effects were considered. Causality is determined using the following criteria: Cases with a likely causality are defi ned as having a clear temporal relationship between ingestion and clinical effects, absence of other reported drugs or absence of diseases which could explain the clinical effects and presence of symptoms which are described for the substance or are plausible from a pharmacodynamic point of view. Cases which fulfi ll the above-mentioned criteria and have in addition an analytical detection (qualitative or quantitative) of the substance in a body fl uid are defi ned as confi rmed. Causality of asymptomatic cases without analysis of body fl uids cannot be classifi ed according to the above-mentioned criteria. We included these cases according to the reported ingested substance.
Ethics approval
Ethics approval was not required due to the nature of the study design according to the regulations of the Cantonal Ethics Committee Z ü rich, Switzerland.
Data analysis
Confi dence intervals (CI) of seizure rates were estimated using the technique described by Wilson 12 as recommended in the applied statistical literature. 13, 14 Statistical tests of binomial coeffi cients were done using Fisher ' s exact test, those comparing dose samples by the non-parametric Wilcoxon-Mann-Whitney rank-sum test. All data evaluations were performed using the statistics and graphics software R. 15 P values less than 0.05 were considered statistically signifi cant.
The seizure rates in different age groups were calculated by dividing the number of reported cases associated with seizures in an age group by the number of all cases in the same age group.
The seizure potential of a pharmaceutical was calculated by dividing the number of cases associated with seizures by the number of all cases recorded with that drug.
Results
The STIC answered a mean of 31,927 calls per year (range: 29,506 -34,283) during the study period. The referral population was about 7.1 million people at the beginning and about 7.8 million people at the end of the study period.
Over the 14-year study period, 15,441 cases met the inclusion criteria. The patients were between 1 day and 98 years old (Table 1 ). There were 65.0% female and 32.1% male patients. Gender was not reported in 2.9% of the cases. Cases with accidental exposure (34.4%), intentional exposure (64.3%), and exposure by other reasons (1.3%) were recorded. Intentional exposures were mostly suicidal or abusive, exposure by other reasons include iatrogenic exposures or exposures with unknown reason. Analytical confi rmation (quantitative or qualitative) was available in 9.2% of the cases.
At least one seizure was recorded in 313 of the cases. The patients were between 1 year and 90 years old (Table 1 ). There were 70.0% female and 29.7% male patients. Gender was not reported in 0.3% of the cases with seizures. Cases with accidental exposure (13.4%), intentional exposure (85.0%), and exposure by other reasons (1.6%) were recorded. Analytical confi rmation (quantitative or qualitative) was available in 15.3% of the cases with seizures.
In the 313 cases with seizures 61 different pharmaceutical drugs were involved. Nineteen drugs were associated with three or more cases with seizures ( Fig. 1) . The most prevalent drug was mefenamic acid (51 cases, 16.3%), followed by citalopram (34 cases, 10.9%), trimipramine (27 cases, 8.6%), venlafaxine (23 cases, 7.3%), tramadol (15 cases, 4.8%), diphenhydramine (14 cases, 4.5%), amitriptyline (12 cases, 3.8%), carbamazepine (11 cases, 3.5%), maprotiline (10 cases, 3.2%), quetiapine (10 cases, 3.2%), fl uoxetine (9 cases, 2.9%), dextromethorphan (8 cases, 2.6%), chlorprothixene (8 cases, 2.6%), bupropion (6 cases, 1.9%), tolperisone (5 cases, 1.6%), clozapine (4 cases, 1.3%), clomipramine (4 cases, 1.3%), olanzapine (3 cases, 1.0%), and methadone (3 cases, 1.0%). These 19 pharmaceuticals were responsible for 82% (257/313) of all cases. The seizures in the remaining 56 cases were associated with 42 further drugs with 14 pharmaceuticals associated with two cases with sei-zures each (bupivacaine, clotiapine, codeine, dibenzepin, doxepin, fl uvoxamine, ioxaglic acid, isoniazid, lamotrigine, lidocaine, opipramol, phenobarbital, propranolol and verapamil) and a wide variety of 28 pharmaceuticals associated with one case with seizures each (see online Supplementary Data available online at http://informahealthcare.com/doi/ abs/10. 3109/15563650.2014.918627) . Antidepressants (AD) were associated with 136 cases with seizures (43.5%), antipsychotics with 30 (9.6%), and antiepileptics with 17 (5.4%) cases ( Table 2) .
The highest seizure potential was found with bupropion. Seizures were recorded in 31.6% (6/19 cases; 95% CI: 15.4 -54.0%). It was followed by maprotiline 17.5% (10/57 cases; 95% CI: 9.8 -29.4%), venlafaxine 13.7% (23/168 cases; 95% CI: 9.3 -19.7%), citalopram 13.1% (34/259 cases; 95% CI: 9.5 -17.8%) and mefenamic acid 10.9% (51/470 cases; 95% CI: 8.4 -14.0%) (Fig. 2) .
The 313 cases with seizures result in a seizure rate of 2.0% (313/15,441) . Table 1 shows the seizure rates in the different age groups. The difference between the rate of 4.3% in adolescents (15 -19y/o) and the rate of 2.3% in adults ( Ն 20y/o) is statistically signifi cant ( p Ͻ 0.001). Regarding this age difference we calculated the rates for the four pharmaceuticals with most seizure cases. For mefenamic acid the difference of the rates between adolescents 23.9% (95% CI: 17.6 -31.7%) and adults 5.7% (95% CI: 3.3 -9.7%) was signifi cant ( p Ͻ 0.001). For citalopram the seizure rates for adolescents and adults were 22.0% (95% CI: 12.8 -35.2%) and 10.9% (95% CI: 7.1 -16.4%), respectively ( p ϭ 0.058). No age difference could be found for trimipramine ( p ϭ 0.73) and venlafaxine ( p ϭ 0.48). If we exclude the 51 cases with mefenamic acid from the 313 cases, the difference in rates between adolescents and adults was no more signifi cant ( p ϭ 0.17). The seizure rates for adolescents and adults were 2.8% (95% CI: 2.1 -3.7%) and 2.2% (95% CI: 1.9 -2.6%), respectively.
To exclude a dose effect causing the age difference in mefenamic acid and citalopram cases, we calculated the medians of the reported ingested doses for the two drugs. There was no signifi cant difference of the doses between adolescents and adults. For mefenamic acid the median doses were 8.5g (131.1mg/kg) in adolescents and 10.0g (130.3mg/kg) in adults ( p ϭ 0.39 for dose in g, p ϭ 0.74 for dose in mg/kg). Dose as reported by the patient or a caregiver was available in 92.2% of the cases with seizures and in 84.7% of all cases. The median of the ingested doses for citalopram were 1.0g (15.6mg/kg) and 1.3g (19.7mg/kg), respectively ( p ϭ 0.35 and 0.70). Dose as reported by the patient or a caregiver was available in 85.3% of the cases with seizures and in 86% of all cases. Table 3 shows the ranges and medians of the ingested doses of the four pharmaceuticals most commonly associ-ated with seizures. The probability of seizures increased as the dose increased and the difference between the medians of the ingested doses in cases with and without seizures was signifi cant with p Ͻ 0.001 for each of the four agents.
Discussion
Drugs involved
In the literature only case series are reported which include cases with co-ingestants, no studies were found which analyze only single-agent overdoses associated with drug-induced seizures. In case series the authors assigned the drug with an already described seizure risk to be the likely cause of the convulsions in cases with multi-drug exposures. 4, 6, 10, 11 This could bias the results in cases with ingestion of more than one substance described to cause seizures or in cases with new substances not yet known to cause seizures which are co-ingested with substances with a known seizure risk. The fact that we only considered single-agent exposures strengthens the causal association between the seizures and the ingested pharmaceutical.
As in the present study, all studies so far found high rates of seizures associated with antidepressants (28. 8 -42.4%). 4,6,9 -11 Antidepressants are known to have a considerable potential to cause seizures in overdose, some agents having a seizure rate of greater than 10%. 16 However, the pharmaceutical most often associated with drug-induced seizures in the present study was mefenamic acid. This non-steroidal anti-infl ammatory drug (NSAID) is widely available as an analgesic in Switzerland and a few other countries, but not in the USA and therefore was probably not reported in the aforementioned studies. The other pharmaceuticals which were associated with seizures in more than 5% of the cases in our study are also described in the literature. Thundiyil et al. 4 found the seizure rate for cases with citalopram/escitalopram overdose to be 8.3% and the one for venlafaxine 1.7%. In another study by Thundiyil et al. 10 the seizure rate for venlafaxine was 6%. The proportion of trimipramine-induced seizure is not described in the literature, but in three studies rates of seizures induced by tricyclic antidepressants were between 1.7% and 24.6%. 4, 10, 11 Seizure potential A large number of cases with seizures associated with a particular drug could mean that this drug has a high seizure potential or that it is more often involved in overdose, or both. The studies which analyzed cases with seizures reported so far do not report data about the corresponding cases with the same substance without occurrence of seizures during the time interval studied, therefore seizure potentials cannot be calculated. 4,6 -11 However, there are some studies analyzing clinical effects in overdose of single substances or of drug classes that mention seizure potentials. 17 -21 In our study the highest seizures potential was reached by bupropion. Bupropion overdose was a rare event with only 19 exposures, but these intoxications were associated with seizures in six cases. Bupropion is known to frequently cause seizures in overdose 18, 22 and it was the single drug caus- ing most seizures in three studies. 4, 9, 10 Despite the small number of cases our analysis confi rms the high potential of bupropion to cause seizures in overdose. For maprotiline, venlafaxine, citalopram, and mefenamic acid we found a seizure potential of more than 10%. This considerable risk of seizures in overdose is described in the literature. Seizures occurred in more than 10% of acute maprotiline intoxications, 16, 20, 23 in 4 -13.7% of venlafaxine intoxications, 19,20,24 -27 in 5. 8 -15 .9% of citalopram intoxications 20,21,28 -30 and in 14 -39.3% of mefenamic acid intoxications. 17,31 -33
Seizure rates and age distribution
In the literature rates of seizures associated with intoxications are reported in four case series. 6 -9 In a recent study with cases reported to a toxico-surveillance system seizures occurred in 4.7% of the patients younger than 18 years and in 4.5% of the adult patients. 6 In a retrospective review 1.6% of 1561 children (3 -172 months) admitted for intoxication developed seizures. 7 In another retrospective review seizures occurred in 1.3% of 3687 children (0 -18 years) admitted to a pediatric toxicology department. 8 In a case series with adults 5.2% of 2340 patients admitted to a poisoning treatment center had seizures. 9 In all four case series multiple-agent exposures were also analyzed and substances other than pharmaceutical drugs were included. In our study, which is one of the largest to date describing seizure rates in cases with overdose, we found very low seizure rates of 0.4 and 0.6% in children of 0 -4 and 5 -9 years of age, respectively. In poisonings, seizure rates in children are expected to be lower than in adults since intoxications in children less than 10 years of age are almost exclusively accidental and smaller doses are ingested than in intentional poisonings. The seizure rate of all patients from 0 to 19 years of age was 1.7% and is comparable to the data given by Citak (1.6%) 7 and Nitescu (1.3%), 8 but lower than the one reported by Finkelstein (4.7%). 6 The seizure rate of 2.3% that we found in adults ( Ն 20 y/o) is lower than the rates reported by Kirschner (5.2%) 9 and Finkelstein (4.5%). 6 The differences might be due to our strict inclusion criteria (only single-agent exposures, only pharmaceutical drugs), but could also be a consequence of other reasons, as ingestion of different amounts or substances or a different patient collective.
One interesting result of our study is the higher seizure rate in adolescents (15 -19 y/o) compared to adults ( Ն 20y/o), which is almost exclusively due to the cases with mefenamic acid. An age dependency of seizures in mefenamic acid overdose has already been described earlier. In a case series seizures were seen in 22.3% of the cases in 16 -20 year olds, but only in 7.1% of patients older than 20 years. 33 Also in the cases with citalopram adolescents had more seizures than adults, but this difference was statistically not signifi cant. The most obvious reason for an apparent age dependency of seizures would be that adolescents could have ingested higher doses, since a dose dependency for occurrence of seizures is well described. 22, 30, 34 However, we could not fi nd a signifi cant difference of the medians of the ingested doses of mefenamic acid or citalopram in the two groups. Furthermore, adolescents could genuinely be more susceptible to seizures. It is known that during adolescence important changes take place in the brain, such as remodeling of synaptic connections. 35 There is also some evidence from animal models that during adolescence susceptibility to seizures is increased 36, 37 and reported annual incidence rates of epilepsy are higher in patients of 10 -19 years of age than in adults. 38
Ingested dose and probability of seizures
Dose dependency of occurrence of seizures is well-known in cases of drug overdose 34 and is reported in the literature for mefenamic acid, 17,32,33 citalopram, 21,28,29 trimipramine 39 and venlafaxine. 19 The results in the literature and of our study support the mechanistic view of the pathophysiology of seizures in overdose which are thought to be provoked by overexcitation of the brain by different pathways in a dose-dependent manner. 5,40
Limitations
This study has several limitations due to the inherent nature of poison center data. 41 The study has a retrospective design and certain information might be missing in some of the cases. Some clinical effects might be underreported, but seizures are an obvious effect and recording is quite probable. Reporting to poison centers is voluntary and the seizure rate could be overestimated because the poison center might not be called for advice in cases with minor ingestions or in cases with substances the treating physician is familiar with. The ingested substances are based mainly on reports of the patient or caregivers in cases involving children. Analytical confi rmation was available only in a minority of the cases, so we cannot exclude defi nitely that other substances have been co-ingested. We did not consider factors as dose, age, or comorbidities in calculating the seizure potential which could infl uence the result. So it cannot be excluded that pharmaceuticals with a high seizure potential were taken in a higher relative dose or by a different age group than drugs with a lower seizure potential. But the drugs we found to have a high seizure potential are described in the literature as frequently causing seizures in overdose. Our results can only partly be generalized as the frequency of use of pharmaceutical drugs may vary considerably among different countries. Our strict inclusion/exclusion criteria with exclusion of multiple-agent exposures result in smaller case numbers. However, the inclusion of only single-agent exposures favors a correct interpretation of the results, seizures do not have to be assigned to one of the drugs ingested and interactions between different pharmaceuticals can be excluded.
Conclusions
Our study confi rms that antidepressants play an important role in overdose-induced seizures, many substances with a high seizure potential are found in this drug class. But a variety of other pharmaceutical drugs, as mefenamic acid can also be frequently associated with seizures in overdose. The most frequent pharmaceuticals associated with seizures do not necessarily have the highest seizure potential. This was shown for bupropion, which has a very high seizure potential, but was only involved in 1.9% of the cases with seizures, in comparison to mefenamic acid, which was the most prevalent drug associated with seizures, but has a lower seizure potential than bupropion. Adolescents were more likely to develop seizures than adults with mefenamic acid. This fi nding deserves further consideration for other substances. The probability of seizures with mefenamic acid, citalopram, trimipramine, and venlafaxine increased as the ingested dose increased.
